Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
Nath CE, Trotman J, Tiley C, Presgrave P, Joshua D, Kerridge I, Kwan YL, Gurney H, McLachlan AJ, Earl JW, Nivison-Smith I, Zeng L, Shaw PJ. Nath CE, et al. Among authors: joshua d. Br J Clin Pharmacol. 2016 Jul;82(1):149-59. doi: 10.1111/bcp.12906. Epub 2016 Apr 27. Br J Clin Pharmacol. 2016. PMID: 26879446 Free PMC article.
Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.
Ho PJ, Brown RD, Spencer A, Jeffels M, Daniher D, Gibson J, Joshua DE. Ho PJ, et al. Among authors: joshua de. Leuk Lymphoma. 2012 Sep;53(9):1728-34. doi: 10.3109/10428194.2012.664842. Epub 2012 Mar 13. Leuk Lymphoma. 2012. PMID: 22329352 Clinical Trial.
The T Cell in Myeloma.
Joshua D, Suen H, Brown R, Bryant C, Ho PJ, Hart D, Gibson J. Joshua D, et al. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):537-542. doi: 10.1016/j.clml.2016.08.003. Epub 2016 Aug 10. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27601001 Review.
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.
Horvath N, Spencer A, Kenealy M, Joshua D, Campbell PJ, Lee JJ, Hou J, Qiu L, Kalff A, Khong T, Londhe A, Siggins S, van Kooten Losio M, Eisbacher M, Prince HM. Horvath N, et al. Among authors: joshua d. Leuk Lymphoma. 2019 Sep;60(9):2122-2133. doi: 10.1080/10428194.2019.1579322. Epub 2019 Feb 19. Leuk Lymphoma. 2019. PMID: 30777794 Clinical Trial.
Biology and therapy of multiple myeloma.
Joshua DE, Bryant C, Dix C, Gibson J, Ho J. Joshua DE, et al. Med J Aust. 2019 May;210(8):375-380. doi: 10.5694/mja2.50129. Epub 2019 Apr 23. Med J Aust. 2019. PMID: 31012120 Review.
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.
Ho PJ, Spencer A, Mollee P, Bryant CE, Enjeti AK, Horvath N, Butcher BE, Trotman J, Gibbs S, Joshua DE. Ho PJ, et al. Among authors: joshua de. Clin Lymphoma Myeloma Leuk. 2024 Apr 7:S2152-2650(24)00149-6. doi: 10.1016/j.clml.2024.04.001. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38702217
Multiple myeloma: challenges and opportunities.
Joshua D, Brown R, Ho PJ. Joshua D, et al. Methods Mol Med. 2005;113:1-4. doi: 10.1385/1-59259-916-8:1. Methods Mol Med. 2005. PMID: 15968090 Review. No abstract available.
243 results